Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Knight Therapeutics Inc
T.GUD
Alternate Symbol(s):
KHTRF
Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select...
international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:GUD)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(13)
•••
gudisgood
X
View Profile
View Bullboard History
Comment by
gudisgood
on Mar 31, 2023 4:33am
RE:Remember back to Samira's last forecast ...
Just a correction: the initial revenue guidance for 2022 was $260-$265M if I'm not mistaken? Midpoint was $262.5M compared to the $293.5M that we ended up with. 2022 included the $6M settlement
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Post by
MrMugsy
on Mar 30, 2023 11:14pm
Remember back to Samira's last forecast ...
Remember when Samira forecasted 2022 revenue? It was $250MM-$260MM. The forecast ended up creeping to $270MM and we hit over $290MM. Here we go with a fairly high initial revenue estimate and
...more
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
posted Nov 14, 2024 9:00am by
NurExone Biologic Inc.
-
|
“We are honored by the EMA’s recognition of ExoPTEN through the Orphan Medicinal Product Designation, which significantly advances our ability to enter the European market and offers hope to those impacted by acute spinal cord injuries,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “This designation, together with the ...read more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Mar 30, 2023 10:49pm
RE:RE:Annual Report & Annual Information Form Published
Does what make sense Wofat? I don't see a question except ... hurry up and wait? What are you asking to be validated? And if you want "validation," then you should ask Samira.
...more
(8)
•••
wofats
X
View Profile
View Bullboard History
Comment by
wofats
on Mar 30, 2023 8:58pm
RE:Annual Report & Annual Information Form Published
G2S2 Capital Inc. just added a bit over 800,000 shares to bring their holdings to over 12,000,000 shares.
(8)
•••
wofats
X
View Profile
View Bullboard History
Comment by
wofats
on Mar 30, 2023 7:40pm
RE:Annual Report & Annual Information Form Published
Does this make sense? I am looking for validation Not cheerleading . These additions will be complementing the regular business of the company for the first quarter. Most of them were added
...more
(8)
•••
hoffbag
X
View Profile
View Bullboard History
Post by
hoffbag
on Mar 30, 2023 7:36pm
People still look at this?
This was a dog 2 years ago when I looked at it. Still is but a cheaper one. Company still buying shares? May as well take it private.
(13)
•••
gudisgood
X
View Profile
View Bullboard History
Post by
gudisgood
on Mar 30, 2023 3:57am
Annual Report & Annual Information Form Published
... also, 800K shares bought back since the Q4 report. :)
(17)
•••
GoldenInvestor
X
View Profile
View Bullboard History
Post by
GoldenInvestor
on Mar 29, 2023 8:24am
Drug shortages & orphan drugs
& production shortages . Discussed on CNBC this am w meg tirrell
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Post by
Chianchin
on Mar 27, 2023 5:12pm
GUD implied promises on past Paladin success
Regretably the Paladin Jeene did show up and the lamp went dark. The share price capitulation will continue as I "suspect" GUD MNGT has come to relize that keeping GUD share price above $5
...more
(141)
•••
Eoj123
X
View Profile
View Bullboard History
Comment by
Eoj123
on Mar 27, 2023 2:54pm
RE:RE:Gudisbad is pleased with the results
Another buck down, keep repeating this phrase, This is for the grandkids, This is for the grandkids
(6)
•••
curiousj
X
View Profile
View Bullboard History
Comment by
curiousj
on Mar 27, 2023 9:51am
RE:RE:Results
Knight will continue to be in a position to execute on BD opportunity. what about the ROI on current business though... especially given how low GM% are. What are the opportunities to scale
...more
(13)
•••
gudisgood
X
View Profile
View Bullboard History
Comment by
gudisgood
on Mar 27, 2023 4:31am
RE:2023 Guidance
I agree that they could expand more on how they see the future and how the recent years have been in relation to what they expected and in relation to what the "average" environment is in
...more
(13)
•••
gudisgood
X
View Profile
View Bullboard History
Comment by
gudisgood
on Mar 27, 2023 2:38am
RE:Gudisbad is pleased with the results
I am pleased, or at least pleasantly surprised, by the Q4 results -- well over the guidance. I would have hoped for a stronger 2023 guidance, though. So I cannot say that I'm "pleased"
...more
(3)
•••
Chianchin
X
View Profile
View Bullboard History
Post by
Chianchin
on Mar 25, 2023 12:37pm
Gudisbad is pleased with the results
I agree if the opposite is the quest. Losing fortunes is good and making profits is bad. Where does this person come from. I know it is mr mugsy in hiding
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Have you held units of a TD mutual fund (other than through a discount broker)? Learn more.
Geodrill Generates Revenue of $34.1M, a 13% Increase Compared to $30.3M for Q3-2023
Gold, growth and sustainability in focus for this resource company
Star Diamond Corporation Announces Third Quarter 2024 Results
Coppernico Drills 19 Meters of 0.50% Copper in First 5 Holes and Applies for Additional Permits
Explained: The Psychology of Options Trading with Practical Tips
Meet the Top 5 Best Online Brokerages in Canada
Major Funding Secured! Company Closes First Round of Private Placement